Kamada (KMDA) Common Equity (2012 - 2026)
Kamada (KMDA) posted quarterly Common Equity of $259.4 million for Q1 2026, up 2.95% year-on-year from $252.0 million in Q1 2025, and down 3.6% on a QoQ basis from $269.1 million in Q4 2025.
Kamada (KMDA) Common Equity (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Common Equity for 15 consecutive years, with $259.4 million the latest figure, recorded in Q1 2026.
- Quarterly Common Equity rose 2.95% year-over-year to $259.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.4 million (up 2.95% YoY) and the FY2025 annual result came in at $269.1 million, up 3.7% from the prior year.
- Common Equity retreated to $259.4 million in Q1 2026 per KMDA's latest filing, from $269.1 million in the prior quarter.
- Over the last five years, Common Equity for KMDA reached as high as $269.1 million in Q4 2025 and fell as low as $171574.0 in Q2 2022.
- A 5-year average of $206.4 million and a median of $251.2 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity sank 99.91% — and 2023, when it jumped 138056.26%.
- Year by year, Common Equity stood at $176.0 million in 2022, then soared by 38.63% to $244.0 million in 2023, then rose by 6.33% to $259.5 million in 2024, then gained by 3.7% to $269.1 million in 2025, then retreated by 3.6% to $259.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $259.4 million, $269.1 million, and $265.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 259.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 259.39 Mn |
| Dec 31, 2025 | 269.07 Mn |
| Sep 30, 2025 | 265.23 Mn |
| Jun 30, 2025 | 259.95 Mn |
| Mar 31, 2025 | 251.96 Mn |
| Dec 31, 2024 | 259.46 Mn |
| Sep 30, 2024 | 255.27 Mn |
| Jun 30, 2024 | 251.15 Mn |
| Mar 31, 2024 | 251.15 Mn |
| Dec 31, 2023 | 244.02 Mn |
| Sep 30, 2023 | 238.39 Mn |
| Jun 30, 2023 | 176.75 Mn |
| Mar 31, 2023 | 174.81 Mn |
| Dec 31, 2022 | 176.02 Mn |
| Sep 30, 2022 | 172,551.00 |
| Jun 30, 2022 | 171,574.00 |
| Mar 31, 2022 | 175.15 Mn |
| Dec 31, 2021 | 176.82 Mn |
| Sep 30, 2021 | 181.61 Mn |
| Jun 30, 2021 | 182.34 Mn |